Octaplasmalg (B) (Human Plasma Protein)

Human plasma protein in Octaplasmalg (B) provides a broad spectrum of functional clotting factors, albumin, and other plasma proteins. By restoring these components, the product re‑activates the intrinsic and extrinsic coagulation pathways, improves oncotic pressure, and supports overall hemostasis, helping the body to stop bleeding and maintain circulatory stability.

The dose of Octaplasmalg (B) is individualized and determined by the prescribing clinician based on the patient’s weight, severity of bleeding, laboratory values, and clinical situation. Healthcare professionals calculate the required volume to achieve target coagulation factor levels and plasma volume replacement.

Safety data for Octaplasmalg (B) in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician in consultation with obstetric specialists.

To order Octaplasmalg (B), submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Octaplasmalg (B) is a solvent/detergent‑treated plasma product, offering a standardized, pathogen‑reduced alternative to fresh frozen plasma (FFP). It provides consistent clotting factor levels, a longer shelf‑life, and reduced risk of viral transmission, while still delivering the same broad spectrum of plasma proteins needed for hemostasis.

Octaplasmalg (B) must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. Before use, allow the product to reach room temperature if required by the administration protocol, and inspect for any discoloration or particulate matter.

Octaplasmalg (B) is administered intravenously. The solution is infused through a dedicated IV line, typically using a controlled infusion pump or gravity drip, according to the prescriber’s instructions. Vital signs and coagulation parameters are monitored throughout the infusion to ensure safety and efficacy.

Serious risks include severe allergic reactions such as anaphylaxis, transfusion‑related acute lung injury (TRALI), severe hypotension or shock, hemolytic transfusion reactions, and the rare possibility of viral transmission despite donor screening. Immediate medical intervention is required if any of these events occur.

Octaplasmalg (B) should be avoided in patients with known hypersensitivity to human plasma proteins, a history of severe transfusion reactions, or those who have received incompatible plasma. Caution is also advised for individuals with uncontrolled heart failure, severe renal impairment, or active disseminated intravascular coagulation, where volume overload could be hazardous.